Story thread · 18 reports / 3 sources
Sionna Therapeutics stock plunged 92% after its cystic fibrosis drug flopped in a mid-stage trial
qz.com · 9h
The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study
First report: Piper Sandler downgrades Samsara stock rating on valuation — investing.com, 1d
The coverage
- Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
finance.yahoo.com · 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.